Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Tarken Winn who wrote (3073)	5/18/1999 9:50:00 AM
From: shero	Read Replies (1) \| Respond to of 3702

I don't know what press release you're reading. I think this is the worst press release yet from the company. Nowhere did it say 11 of 12 patients are alive. And its not true anyway. For the sake of accuracy I'm pasting this from the press release-- "Although the twelve patient Phase I study was designed to determine the safety of Cotara(TM) with glioblastoma patients, the median time to progression and median time to survival data was very encouraging. The study results indicated that 50% of the patients were observed to have shrinkage/stabilization of their tumors post treatment, with approximately one-third of a therapeutic dose administered." Surely they could have said more. Its almost as if management doesn't want the news out and the price up.